SDC TABLE 5: GRADE Profile for rVIIa vs. No rVIIa

		DICO 3 (Juality Ass	- Caramont				Summary	Summary of Findings	
		rVII	rVIIa vs. No rVIIa	/Па				No of Patients	of Patients	
Participants (studies)	Risk of Bias	Risk of Bias Inconsistency Indirectness Imprecision	Indirectness	Imprecision	Publication Bias	Quality of Evidence	Hemostatic Adjunct	No Adjunct	Relative (95% CI)	Absolute
Mortality (I	Mortality (Hospital, 28 or 30 Day)	or 30 Day)								
1292 (5)	Serious ¹	No	oN	oN		⊕⊕OO Low¹	112/517 (21.7%)	237/775	0.88 (0.64, 1.2)	26 fewer per 1000 (from 40 more to 86
Blood produ	ucts used (RI	Blood products used (RBC in 24, 48, or 72 H)	or 72 H)							
933 (4)	Zo	No	Serious ²	No	ı	⊕⊕OO Low	424	509	ı	0.92 fewer (2.31 fewer to 0.47 more)
MT										
773 (2)	No	Very Serious ³	No	No	ı	⊕⊕OO Low³	137/371 (36.9%)	185/402 (46%)	0.68 (0.5, 0.92)	93 fewer per 1000 (from 21 fewer to 161 fewer)
VTE (DVT or PE)	or PE)									
1061 (4)	No	No	No	Serious ⁴	-	⊕⊕OO Low ⁴	48/497 (9.9%)	57/574 (9.9%)	3 fewer per 0.97 1000 (from (0.49, 1.92) 48 fewer to 75 more)	3 fewer per 1000 (from 48 fewer to 75 more)

Included retrospective studies with moderate to high risk of bias

²RBC used as a surrogate for total blood products
³High heterogeneity in a small number of studies and/or significant disparities in patient populations
⁴Few reported events with wide confidence intervals

thromboembolic event DVT, deep venous thrombosis; MT, massive transfusion; PE, pulmonary embolism; RBC, red blood cells; VTE, venous